Prince Pharmaceutical Co (ROCO:6935) EBIT: NT$114 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
60 GF Score
Price NT$30.15
GF Value NT$42.11
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co EBIT?

Prince Pharmaceutical Co ROCO:6935 -0.50% 60 EBIT is NT$114 Mil as of Dec. 2025. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.11 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Prince Pharmaceutical Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$87 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$114 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Prince Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 was 14.46%. Prince Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 16.32%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Prince Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.18%.

Prince Pharmaceutical Co  (ROCO:6935) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Prince Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=168.91 * ( 1 - 4.82% )/( (1110.034 + 1113.968)/ 2 )
=160.768538/1112.001
=14.46 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1358.854 - 171.966 - ( 76.854 - max(0, 246.062 - 401.805+76.854))
=1110.034

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1503.486 - 236.901 - ( 152.617 - max(0, 309.905 - 560.889+152.617))
=1113.968

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Prince Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=174.474/( ( (945.359 + max(122.733, 0)) + (932.723 + max(136.954, 0)) )/ 2 )
=174.474/( ( 1068.092 + 1069.677 )/ 2 )
=174.474/1068.8845
=16.32 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(122.811 + 172.968 + 3.311) - (171.966 + 0 + 4.391)
=122.733

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(167.644 + 205.565 + 5.582) - (236.901 + 0 + 4.936)
=136.954

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Prince Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=114.322/1397.324
=8.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co EBIT Related Terms

Prince Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co EBIT Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -2.75 73.14 29.63 -41.82 114.32

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.27 -19.68 -22.14 27.09 87.24

ROCO:6935 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prince Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Prince Pharmaceutical Co's EV-to-EBIT falls into.


ROCO:6935
60GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$114 Mil mean?
Prince Pharmaceutical Co (ROCO:6935) has a EBIT of NT$114 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Prince Pharmaceutical Co.
Is Prince Pharmaceutical Co's EBIT too high?
Prince Pharmaceutical Co's current EBIT is NT$114 Mil. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's EBIT compare to ZTS and UTHR?
Prince Pharmaceutical Co's EBIT of NT$114 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Prince Pharmaceutical Co. Prince Pharmaceutical Co's current EBIT is NT$114 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.11, compared to a current price of NT$30.15 — trading 28.4% below its estimated fair value. The current EBIT is NT$114 Mil. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current EBIT is NT$114 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$30.15 is trading 28.4% below its estimated GF Value™ of NT$42.11. GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6935:

  • EBIT: NT$114 Mil
  • GF Value™: NT$42.11 vs. price of NT$30.15 (28.4% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score

Get the complete analysis for ROCO:6935

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.15
Price
NT$42.11
GF Value